Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7671MR)

This product GTTS-WQ7671MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in B-cell malignancies research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Chimeric
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7671MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8225MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HLX-06
GTTS-WQ4962MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ3916MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ5066MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ10204MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LDP-02
GTTS-WQ9520MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ1060MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ8508MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Hu3F8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW